Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Clinical Implications of Metastatic Nodal Burden: Stratifying Risk in Resected N1 and N2 NSCLC.

Created on 22 Sep 2026

Authors

Shia Kim, Geun Dong Lee, Sehoon Choi, Hyeong Ryul Kim, Yong-Hee Kim, Dong Kwan Kim, Seung-Il Park, Bokyung Ahn, Jae Kwang Yun

Published in

Annals of surgical oncology. Sep 21, 2026. Epub Sep 21, 2026.

Abstract

Current anatomical N staging often fails to reflect prognostic heterogeneity within N1 and N2 non-small cell lung cancer (NSCLC). We evaluated whether metastatic nodal burden, defined as the tumor deposit size, provides additional prognostic information beyond conventional staging.
We retrospectively analyzed 1495 patients with pN1 (n = 633) or pN2 (n = 862) NSCLC who underwent curative surgical resection between 2010 and 2019. Metastatic tumor deposit size was categorized as ≤ 5 mm, 5-9 mm, and ≥ 10 mm. Linearity between tumor size and overall survival (OS) or recurrence-free survival (RFS) was assessed using restricted cubic splines. Kaplan-Meier and multivariable Cox regression analyses were performed.
Median metastatic deposit size was 5 mm (interquartile range [IQR] 3-9) in pN1 and 10 mm (IQR 5.1-16) in pN2. In pN1, high-burden patients (≥ 10 mm) had significantly worse 5-year outcomes than low-burden group (OS: 60.0% versus 75.5%, hazard ratio [HR] 1.66; RFS: 42.2% versus 50.9%, HR 1.83). In pN2, burden independently predicted RFS (5-year rate: 26.2% for ≥ 10 mm versus 42.4% for < 5 mm; HR 1.72, p < 0.001). Notably, radiologically occult low-burden metastasis (< 5 mm) was prevalent (41% in pN1, 19% in pN2) and associated with favorable survival, yet frequently undetectable on standard preoperative imaging.
Metastatic nodal burden reflects meaningful prognostic variation within pN1 and pN2 disease. These findings suggest that considering metastatic burden may help refine postoperative risk assessment and support more individualized management in surgically treated NSCLC.

PMID:
42766269
Bibliographic data and abstract were imported from PubMed on 22 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 9
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement